Home
In this issue

Jonathan Tobin: Defending the Right to a Jewish State

Heather Hale: Compliment your kids without giving them big heads

Megan Shauri: 10 ways you are ruining your own happiness

Carolyn Bigda: 8 Best Dividend Stocks for 2015

Kiplinger's Personal Finance editors: 7 Things You Didn't Know About Paying Off Student Loans

Samantha Olson: The Crucial Mistake 55% Of Parents Are Making At Their Baby's Bedtime

Densie Well, Ph.D., R.D. Open your eyes to yellow vegetables

The Kosher Gourmet by Megan Gordon With its colorful cache of purples and oranges and reds, COLLARD GREEN SLAW is a marvelous mood booster --- not to mention just downright delish
April 18, 2014

Rabbi Yonason Goldson: Clarifying one of the greatest philosophical conundrums in theology

Caroline B. Glick: The disappearance of US will

Megan Wallgren: 10 things I've learned from my teenagers

Lizette Borreli: Green Tea Boosts Brain Power, May Help Treat Dementia

John Ericson: Trying hard to be 'positive' but never succeeding? Blame Your Brain

The Kosher Gourmet by Julie Rothman Almondy, flourless torta del re (Italian king's cake), has royal roots, is simple to make, . . . but devour it because it's simply delicious

April 14, 2014

Rabbi Dr Naftali Brawer: Passover frees us from the tyranny of time

Greg Crosby: Passing Over Religion

Eric Schulzke: First degree: How America really recovered from a murder epidemic

Georgia Lee: When love is not enough: Teaching your kids about the realities of adult relationships

Cameron Huddleston: Freebies for Your Lawn and Garden

Gordon Pape: How you can tell if your financial adviser is setting you up for potential ruin

Dana Dovey: Up to 500,000 people die each year from hepatitis C-related liver disease. New Treatment Has Over 90% Success Rate

Justin Caba: Eating Watermelon Can Help Control High Blood Pressure

The Kosher Gourmet by Joshua E. London and Lou Marmon Don't dare pass over these Pesach picks for Manischewitz!

April 11, 2014

Rabbi Hillel Goldberg: Silence is much more than golden

Caroline B. Glick: Forgetting freedom at Passover

Susan Swann: How to value a child for who he is, not just what he does

Cameron Huddleston: 7 Financial Tasks You Should Tackle Right Now

Sandra Block and Lisa Gerstner: How to Profit From Your Passion

Susan Scutti: A Simple Blood Test Might Soon Diagnose Cancer

Chris Weller: Have A Slow Metabolism? Let Science Speed It Up For You

The Kosher Gourmet by Diane Rossen Worthington Whitefish Terrine: A French take on gefilte fish

April 9, 2014

Jonathan Tobin: Why Did Kerry Lie About Israeli Blame?

Samuel G. Freedman: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Jessica Ivins: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Kim Giles: Asking for help is not weakness

Kathy Kristof and Barbara Hoch Marcus: 7 Great Growth Israeli Stocks

Matthew Mientka: How Beans, Peas, And Chickpeas Cleanse Bad Cholesterol and Lowers Risk of Heart Disease

Sabrina Bachai: 5 At-Home Treatments For Headaches

The Kosher Gourmet by Daniel Neman Have yourself a matzo ball: The secrets bubby never told you and recipes she could have never imagined

April 8, 2014

Lori Nawyn: At Your Wit's End and Back: Finding Peace

Susan B. Garland and Rachel L. Sheedy: Strategies Married Couples Can Use to Boost Benefits

David Muhlbaum: Smart Tax Deductions Non-Itemizers Can Claim

Jill Weisenberger, M.S., R.D.N., C.D.E : Before You Lose Your Mental Edge

Dana Dovey: Coffee Drinkers Rejoice! Your Cup Of Joe Can Prevent Death From Liver Disease

Chris Weller: Electric 'Thinking Cap' Puts Your Brain Power Into High Gear

The Kosher Gourmet by Marlene Parrish A gift of hazelnuts keeps giving --- for a variety of nutty recipes: Entree, side, soup, dessert

April 4, 2014

Rabbi David Gutterman: The Word for Nothing Means Everything

Charles Krauthammer: Kerry's folly, Chapter 3

Amy Peterson: A life of love: How to build lasting relationships with your children

John Ericson: Older Women: Save Your Heart, Prevent Stroke Don't Drink Diet

John Ericson: Why 50 million Americans will still have spring allergies after taking meds

Cameron Huddleston: Best and Worst Buys of April 2014

Stacy Rapacon: Great Mutual Funds for Young Investors

Sarah Boesveld: Teacher keeps promise to mail thousands of former students letters written by their past selves

The Kosher Gourmet by Sharon Thompson Anyone can make a salad, you say. But can they make a great salad? (SECRETS, TESTED TECHNIQUES + 4 RECIPES, INCLUDING DRESSINGS)

April 2, 2014

Paul Greenberg: Death and joy in the spring

Dan Barry: Should South Carolina Jews be forced to maintain this chimney built by Germans serving the Nazis?

Mayra Bitsko: Save me! An alien took over my child's personality

Frank Clayton: Get happy: 20 scientifically proven happiness activities

Susan Scutti: It's Genetic! Obesity and the 'Carb Breakdown' Gene

Lecia Bushak: Why Hand Sanitizer May Actually Harm Your Health

Stacy Rapacon: Great Funds You Can Own for $500 or Less

Cameron Huddleston: 7 Ways to Save on Home Decor

The Kosher Gourmet by Steve Petusevsky Exploring ingredients as edible-stuffed containers (TWO RECIPES + TIPS & TECHINQUES)

Jewish World Review

Diabetes drug found to reduce cancer risk

By Thomas H. Maugh II




http://www.JewishWorldReview.com | (MCT) A growing body of evidence suggests that the widely used diabetes drug metformin can reduce the risk of cancer, researchers said Wednesday.

A study in mice exposed to tobacco carcinogens, published Wednesday, shows that the drug can reduce the development of lung tumors by as much as 70 percent, and results from a small clinical trial in Japan suggest it can reduce rates of colorectal tumors in humans. The National Cancer Institute is now organizing a clinical trial to test the drug in people who smoke, and other trials are testing it against breast and prostate cancer.

There is not yet enough evidence to recommend using the drug routinely for cancer prevention, but the evidence is strong enough that physicians and patients considering drug therapy for Type 2 diabetes might want to lean toward metformin because of its ancillary effects, researchers said in a news conference.

"Among the various treatment options for Type 2 diabetes, if all other things are equal, early evidence that metformin might have benefit on the oncology side may play a role in decision making," said Dr. Michael Pollak, a medical oncologist at McGill University in Montreal, who surveyed recent metformin research in an article in the journal Cancer Prevention Research.

The drug is particularly promising, he added, because unlike use of finasteride for preventing prostate cancer or tamoxifen for breast cancer, metformin appears to act across a broad spectrum of cancers.

Metformin increases the sensitivity of cells to insulin. It is one of the most widely used diabetes drugs, with 40 million prescriptions written in the United States in 2008.

It also has a number of other biological effects, including inhibiting a key signaling process between receptors in cells (called mammalian target of rapamycin, or mTOR) and reducing circulating levels of insulin and insulin-like growth factor. All those actions may inhibit or prevent the growth of cancer cells.

Interest in metformin was stimulated by a 2005 observational study in the United Kingdom that found that diabetics taking metformin had a 40 percent lower risk of cancer than those taking other diabetes drugs. Several subsequent studies have found the same thing.

"The epidemiologic evidence in diabetic humans is convincing and strong," said Dr. Phillip A. Dennis, a medical oncologist at the National Cancer Institute. "It is real, and the reduction in risk ranges from 30 percent to 70 percent," depending on the type of cancer.

To learn more about it, Dennis and his colleagues used a well-known model of lung cancer, exposing mice to a carcinogen known as NKK, the most important carcinogen in tobacco smoke. All the mice given only NKK developed lung cancer, the researchers reported in Cancer Prevention Research.

But mice given metformin orally had a 33 percent reduction in numbers of tumors and a 34 percent reduction in tumor size. Those given it by injection had a 73 percent reduction in tumor number. The NCI is now planning and seeking approval for a clinical trial in human smokers.

In another report in the same journal, researchers from the Yokohama City University School of Medicine and the National Cancer Center Research Institute in Tokyo gave metformin to 12 non-diabetic patients with what are known as aberrant crypt foci, precursors of colorectal cancer.

After a month of low doses of the drug, the scientists found a significantly lower number of foci in the treated patients compared to 14 controls who did not receive the drug.

"These are very promising and exciting results," said Dr. Scott Lippman, a medical oncologist at the University of Texas M.D. Anderson Cancer Center and editor of the journal.

In an editorial accompanying the reports, Dr. Jeffrey A. Engelman of Massachusetts General Hospital and Dr. Lewis C. Cantley of the Beth Israel Deaconess Medical Center in Boston also praised the findings. They noted that "primary care physicians and endocrinologists may consider this information when choosing an anti-diabetes regimen for patients, especially those at a higher risk for developing cancer."

In a news conference, Cantley noted that clinicians will have to rely for now on epidemiological studies because "prevention trials take forever to get done, and metformin is off patent, so no drug company will pay for them."

Added Pollak, "We don't want to ignore the evidence we have now."

Interested in a private Judaic studies instructor — for free? Let us know by clicking here.

Every weekday JewishWorldReview.com publishes inspirational material. Sign up for the daily JWR update. It's free. Just click here.

We want your comments! Please let us know what you think by clicking here.





© 2010, Los Angeles Times Distributed by McClatchy-Tribune Information Services.